Posts by John Bucksath, CEO

John Bucksath, CEO and Board Member at KCAS Bioanalytical and Biomarker Services since 2016, steers the organization's strategy. Also, he actively contributes to the boards of the Missouri Biotechnology Association and BioKansas, serves on the University of Missouri’s Research and Development Advisory Board, and participates in the Mizzou Venture Mentoring Program for life sciences startups.

KCAS-blog-thumb_2024-07_Evolution of a CRO Blogs
Read article The Evolution of a CRO

In today’s drug development efforts, Research and Development has increasingly expanded to include multi-country strategies. Over time, pharmaceutical and biotech companies have made substantial impact on economies where development work is conducted, and some countries have developed strategies (i.e. Australia) to attract this lucrative market via financial incentives and offering…

PATTERN_AMBER_1320x780 News
Read article A Look Back and a Look Forward: KCAS is Prepared for the Next Ride in 2023

With 2022 firmly planted in our rearview mirror, and the planning for the new year essentially complete, we all look forward to a new year with cautious optimism as we wait to…

PATTERN_AMBER_1320x780_3 Blogs
Read article An Introduction to KCAS and How We Help Our Clients

Thank you for your interest in learning about KCAS. Founded in 1979, KCAS has become one of the fastest growing Bioanalytical and Biomarker facilities within our industry. KCAS is a progressive growing contract research…

PATTERN_BLUE_1320x780 Blogs
Read article Evolving to Meet Demand in a Changing Industry

The paradigm of drug development outsourcing is in a period of rapid transition coupled with a growing market in a competitive space. Today’s service providers are hardly recognizable from a decade ago and if the continued evolution in the market is any indicator, it is safe to say the next…

PATTERN_ORANGE_1320x780_3 Blogs
Read article State of the CRO Industry

Once again we find ourselves wrapping up our 2017 goals and  and tallying the year’s performance. Simultaneously, we are filled with excitement looking forward to the New Year and to the promises it will bring to the pharmaceutical industry and the CRO community. According to Reuters, 2017 was one of…